Donaldson Company, Inc. (NYSE: DCI), a heritage provider of innovative filtration products and solutions, announced the acquisition of Univercells Technologies (Belgium), a global provider of innovative biomanufacturing solutions for cell and gene therapy research, development and commercial manufacturing.
Dutch NLC has €20m in first close of new Health Impact Fund
Latest NewsDutch venture builder NLC has announced a €20m first close for its new Health Impact Fund, from which it will invest in 40 startups, both new investments and follow-on. It’s targeting a final close of €100m later this year.
Biosimilars climb the alps
BackgroundGeneric and biosimilar manufacturer Sandoz is expanding with a new biologics production facility in Lendava, Slovenia to prepare for more demand in Europe for biosimilar products.
Sweden: Biobank law
BackgroundThe Sweden Biobank Act governs the collection, storage, and usage of identifiable human material samples for specific purposes.
New Executive Director of Innovative Health Initiative
AppointmentsThe Innovative Health Initiative (IHI) Governing Board has appointed Niklas Blomberg to be the next Executive Director of the organisation. Dr Blomberg has extensive experience of working in Europes life science sector, and is currently Director of ELIXIR, the European life sciences data infrastructure. He will take up his duties at IHI in early 2024.
Cell & Gene Therapies: time for celebration?
Sponsored PublicationsSix years after the first approved cell and gene therapy, the field is living a renaissance. 5 additional FDA-approved therapies were added in 2022 and could be doubled in 2023, setting a new pace to cell & gene therapies. The BioRN Annual Conference on September 29th in Heidelberg will highlight next-generation approaches in the field.
Cell & Gene Therapies: time for celebration?
Sponsored PublicationsSix years after the first approved cell and gene therapy, the field is living a renaissance. 5 additional FDA-approved therapies were added in 2022 and could be doubled in 2023, setting a new pace to cell & gene therapies. The BioRN Annual Conference on September 29th in Heidelberg will highlight next-generation approaches in the field.
French Carthera closes €37.5m Series B financing round
Latest NewsCarthera, a Sorbonne spin-off and developer of an innovative ultrasound-based medical device for the treatment of a wide range of brain disorders, today announced the successful completion of its €37.5m ($40m) Series B financing round.
Donaldson Acquires Belgian Univercells Technologies for €138m
Latest NewsDonaldson Company, Inc. (NYSE: DCI), a heritage provider of innovative filtration products and solutions, announced the acquisition of Univercells Technologies (Belgium), a global provider of innovative biomanufacturing solutions for cell and gene therapy research, development and commercial manufacturing.
Mega Series C in Switzerland
BackgroundAlentis is the only company developing potential treatments for solid cancers and fibrosis targeting Claudin-1 (CLDN1). The molecule is significantly involved in the tight junction between cells. Now the company closed a three digit million Seriec C round.
How to clean with bacteria
BackgroundFrom bacteria to cellulose fibers and lab grown paper. A greek project paves the way to save trees.